Amgen Surpasses Q4 Earnings Forecasts
Biotechnology specialist (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS of $5.08 and revenue of $8.88 billion, but Amgen reported $5.31 in EPS and $9.1 billion in revenue, showcasing double-digit year-on-year growth in both metrics.
Overall, the quarter demonstrated Amgen's effective execution amid a competitive landscape.
Source: Amgen. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.
Source Fool.com
Amgen Inc. Aktie
358,95 €
-1,32 %
Starkes Buy-Sentiment bei Amgen Inc. mit 42 Buy- gegenüber 4 Sell-Einschätzungen.
Ein negatives Potenzial von -5.28% für Amgen Inc., selbst mit einem niedrigeren Kursziel von 340 € als 358.95 €.
